RxDoctor Payments Data

Nabil Azar, MD

Internal Medicine · Mayfield, OHNPI 1164428777

Payments from drug & device makers

$15,684in general payments, 2019–2025

Across 840 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Bayer$813
  • Amgen$748
  • plus $8K from 47 others

What the payments were for

  • Food & beverage$15,660100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,684 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$118,316
Medicare patients
233
Services billed
2,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol61$78,349
RybelsusSemaglutide47$74,757
EliquisApixaban62$68,794
JardianceEmpagliflozin59$60,055
OzempicSemaglutide17$32,921
XareltoRivaroxaban16$24,376
JanumetSitagliptin Phos/Metformin Hcl15$19,249
EntrestoSacubitril/Valsartan16$15,082
MyrbetriqMirabegron14$10,780
LinzessLinaclotide14$8,594
Atorvastatin Calcium768$6,871
Paliperidone ErPaliperidone17$4,909
Semglee (Yfgn) PenInsulin Glargine-Yfgn12$4,583
Levemir FlexpenInsulin Detemir12$4,377
Gabapentin260$3,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$646$107,67864 claims
AstraZenecaFarxiga$1,821$78,34961 claims
PfizerEliquis$1,326$68,79462 claims
Boehringer IngelheimJardiance$498$60,05559 claims
Johnson & JohnsonXarelto$364$24,37616 claims
MerckJanumet$116$19,24915 claims
NovartisEntresto$671$15,08216 claims
Astellas Pharma US IncMyrbetriq$360$10,78014 claims
AbbVieLinzess, Synthroid$2,183$10,72563 claims
Almatica Pharma LLCSertraline Hcl$91$1,243178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Mayfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →